ProQR Therapeutics Net Income 2015-2021 | PRQR

ProQR Therapeutics net income from 2015 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
ProQR Therapeutics Annual Net Income
(Millions of US $)
2020 $-53
2019 $-64
2018 $-44
2017 $-49
2016 $-43
2015 $-23
2014 $-16
2013 $-4
ProQR Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-19
2021-03-31 $-15
2020-12-31 $-16
2020-09-30 $-15
2020-06-30 $-5
2020-03-31 $-18
2019-12-31 $-21
2019-09-30 $-13
2019-06-30 $-13
2019-03-31 $-16
2018-12-31 $-15
2018-09-30 $-7
2018-06-30 $-9
2018-03-31 $-13
2017-12-31 $-13
2017-09-30 $-12
2017-06-30 $-12
2017-03-31 $-11
2016-12-31 $-9
2016-09-30 $-11
2016-06-30 $-11
2016-03-31 $-11
2015-12-31 $-7
2015-09-30 $-7
2015-06-30 $-10
2015-03-31 $0
2014-12-31 $-2
2014-09-30 $-4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.390B $0.011B
ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48